Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and Novabridge Biosciences (NASDAQ:NBP – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.
Profitability
This table compares Xenon Pharmaceuticals and Novabridge Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xenon Pharmaceuticals | N/A | -43.98% | -41.72% |
| Novabridge Biosciences | N/A | N/A | N/A |
Risk and Volatility
Xenon Pharmaceuticals has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Novabridge Biosciences has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500.
Earnings and Valuation
This table compares Xenon Pharmaceuticals and Novabridge Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xenon Pharmaceuticals | $7.50 million | 497.10 | -$345.91 million | ($4.74) | -8.14 |
| Novabridge Biosciences | $3.89 million | 31.46 | -$46.27 million | ($0.36) | -2.93 |
Novabridge Biosciences has lower revenue, but higher earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Novabridge Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.4% of Novabridge Biosciences shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 22.1% of Novabridge Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Xenon Pharmaceuticals and Novabridge Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xenon Pharmaceuticals | 1 | 1 | 11 | 1 | 2.86 |
| Novabridge Biosciences | 1 | 0 | 1 | 0 | 2.00 |
Xenon Pharmaceuticals presently has a consensus target price of $71.31, indicating a potential upside of 84.89%. Novabridge Biosciences has a consensus target price of $9.00, indicating a potential upside of 753.08%. Given Novabridge Biosciences’ higher possible upside, analysts clearly believe Novabridge Biosciences is more favorable than Xenon Pharmaceuticals.
Summary
Novabridge Biosciences beats Xenon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
About Novabridge Biosciences
Novabridge Biosciences, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
